September 30, 2014
Contact: Ben Klein, National Consumers League, firstname.lastname@example.org, (202) 835-3323
Washington, DC - Two consumer organizations today reiterated their support for the Food and Drug Administration’s proposal to allow the same labeling rules for generic drugs as currently required for brand name drugs. The following statement can be attributed to Sally Greenberg, executive director of the National Consumers League and Mike Russo, federal program director of U.S. PIRG.
“Allowing the generic manufacturers to initiate safety updates, as brand-name companies have done for 30 years, is essential to patients and consumers, as promptly updated warnings can provide informed consent to patients and physicians and prevent serious harm to patients. The National Consumers League and U.S. PIRG continue to support in the strongest terms the FDA’s labeling rule for generic drugs. We continue to encourage the FDA to publish a final rule, allowing generic drug manufacturers to unilaterally update their labels as quickly as possible to provide sufficient warnings and protect and inform consumers who take generic drugs.”
See the original letter sent to the FDA on September 9, 2014 here.
About the National Consumers League
The National Consumers League, founded in 1899, is America's pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.